The role of adjuvant radiation therapy for stages III and IV Hodgkin's disease

Seminars in Radiation Oncology

Volumn 6, Issue 3, 1996, Pages 196-209

  Wu, J J ^a   Prosnitz, L R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; HODGKIN DISEASE; HUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION FIELD; REVIEW; TREATMENT FAILURE;

EID: 0030017090     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-4296(96)80016-6     Document Type: Article

References (104)

1. Canellos GP Anderson JR Propert KJ Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD N Engl J Med 327 1992 1478 1484
2. Hancock BW Randomized study of MOPP (mustine Oncovin, procarbazine, prednisone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease Radiother Oncol 7 1986 215 221
3. Jones SE Haut A Weick JK Comparison of adriamycin-containing chemotherapy (MOP-BAP) with MOPP-bleomycin in the management of advanced Hodgkin's disease: A Southwest, Oncology Group study Cancer 51 1983 1339 1347
4. Bonadonna G Valagussa P Santoro A Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease: A report of 8-year results Ann Intern Med 104 1986 739 746
5. Bakemeier RF Anderson JR Costello W BCVPP chemotherapy for advanced Hodgkin's disease: Evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen: Results of the Eastern Cooperative Oncology Group study Ann Intern Med 101 1984 447 456
6. Longo DL Duffey PL Young RC Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure J Clin Oncol 10 1992 210 218
7. Fisher RI DeVita VT Hubbard SP Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse Ann Intern Med 90 1979 761 763
8. Santoro A Bonfante V Bonadonna G Salvage chemotherapy with ABVD in MOPP resistant Hodgkin's disease Cancer Treatment Reports 68 1984 947 951
9. Salvagno L Soraru M Aversa SML Late relapses in Hodgkin's disease: Outcome of patients relapsing more than twelve months after primary chemotherapy Ann Oncol 4 1993 657 662
10. Lohri A Barnett M Fairey RN Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: Identification of risk factors from the British Columbia experience 1970 to 1988 Blood 77 1991 2292 2298
11. Canellos GP Is there an effective salvage therapy for advanced Hodgkin's disease? Ann Oncol 2 suppl 1 1991 1 7
12. Brada M Eeles R Ashley S Salvage radiotherapy in recurrent Hodgkin's disease Ann Oncol 3 1992 131 135
13. Uematsu M Tarbell NJ Silver B Wide-field radiation therapy with or without chemotherapy for patients with Hodgkin, disease in relapse after initial combination chemotherapy Cancer 72 1993 207 212
14. Leigh BR Fox KA Mack CF Radiation therapy salvage of Hodgkin's disease following chemotherapy failure Int J Radiat Oncol Biol Phys 27 1993 855 862
15. Pezner RD Lipsett JA Vora N radical radiotherapy as salvage treatment for relapse of Hodgkin's disease initially treated by chemotherapy alone: Prognostic significance of the disease-free interval Int J Radiat Oncol Biol Phys 30 1994 965 970
16. Roach M III Kapp DS Rosenberg SA Radiotherapy with curative intent: An option in selected patients relapsing after chemotherapy for advanced Hodgkin's disease J Clin Oncol 5 1987 550 555
17. Linch DC Winfield D Goldstone AH Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial Lancet 341 1993 1051 1054
18. Bierman PJ Bagin RG Jagannath S High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long term follow-up in 128 patients Ann Oncol 4 1993 767 773
19. Reece DE Barnett MJ Connors JM Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease J Clin Oncol 9 1991 1871 1879
20. Frei E III Luce JK Gamble JF Combination chemotherapy in advanced Hodgkin's disease: Induction and maintenance of remission Ann Intern Med 79 1973 376 382
21. Young RC Canellos GP Chabner BA Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy Cancer 42 1978 1001 1007
22. Kaplan HS Evidence for a tumoricidal dose level in the radiotherapy of Hodgkin's disease Cancer Res 26 1966 1221 1224
23. Prosnitz LR Roberts KB Combined chemotherapy and radiotherapy for Hodgkin's disease Oncology 6 1992 113 128
24. Longo DL Young RC Wesley M Twenty years of MOPP therapy for Hodgkin's disease J Clin Oncol 4 1986 1295 1306
25. Radford JA Crowther D Rohatiner AZS results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease J Clin Oncol 13 1995 2379 2385
26. Harding MJ McNulty LJ Paul J Mechlorethamine, vinblastine, procarbazine and prednisolone (MVPP) for advanced Hodgkin's disease Eur J Cancer 27 1991 1002 1006
27. Prosnitz LR Farber LR Kapp DS Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data J Clin Oncol 6 1988 603 612
28. Brizel DM Winer EP Prosnitz LR Improved survival in advanced Hodgkin's disease with the use of combined modality therapy Int J Radiat Oncol Biol Phys 19 1990 535 542
29. Wagstaff J Gregory WM Swindell R Prognostic factors for survival in stage IIIB and IV Hodgkin's disease Br J Cancer 58 1988 487 492
30. Carde P MacKintosh FR Rosenberg SA A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy J Clin Oncol 1 1983 146 153
31. Klimo P Connors JM An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV hybrid program Semin Hematol 25 suppl 2 1988 34 40
32. Viviani S Bonadonna G Santoro A Alternating versus hybrid MOPP-ABVD in Hodgkin's disease: The Milan experience Ann Oncol 2 suppl 2 1988 55 62
33. Brusamolino E Orlandi E Morra E Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapy Ann Oncol 5 suppl 2 1994 S53 S57
34. Somers R Carde P Henry-Amar M A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD: A European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial J Clin Oncol 12 1994 279 287
35. Bonfante V Santoro A Viviani S ABVD in the treatment of Hodgkin's disease Semin Oncol 19 suppl 5 1992 38 45
36. Oza AM Ganesan TS Dorreen M Patterns of survival in patients with advanced Hodgkin's disease (HD) treated in a single centre over 20 years Br J Cancer 65 1992 429 437
37. Hancock BW Vaughan Hudson G Vaughan Hudson B British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease Br J Cancer 63 1991 579 582
38. Selby P Patel P Milan S ChlVPP combination chemotherapy for Hodgkin's disease: Long term results Br J Cancer 62 1990 279 285
39. Fischer JJ Papac RJ Theoretical considerations in combinations of localized and systemic therapy for neoplastic disease J Theor Biol 37 1972 105 114
40. Yahalom J Ryu J Straus DJ Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin's diseae treated with alternating chemotherapy combinations J Clin Oncol 9 1991 2193 2201
41. Fabian CJ Mansfield CM Dahlberg S Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease: A Southwest Oncology Group Randomized study Ann Intern Med 120 1994 903 912
42. Mundt AJ Sibley G Williams S Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease Int J Radiat Oncol Biol Phys 33 1995 261 270
43. Bartlett NL Rosenberg SA Hoppe RT Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report J Clin Oncol 13 1995 1080 1088
44. Cullen MH Stuart NSA Woodroffe C ChlVPP/PABlOE and radiotherapy in advanced Hodgkin's disease J Clin Oncol 12 1994 779 787
45. Longo DL Russo A Duffey PL Treatment of advanced-stage massive mediastinal Hodgkin's disease: The case for combined modality treatment J Clin Oncol 9 1991 227 235
46. Young CW Straus DJ Myers J Multidisciplinary treatment of advanced Hodgkin's disease by an alternating chemotherapeutic regimen on MOPP/ABDV and low-dose radiation therapy restricted to originally bulky disease Cancer Treatment Reports 66 1982 907 914
47. Tannock IF Hill RP The Basic Science of Oncology 1987 Pergamon Press New York, NY
48. Hancock BW Vaughan Hudson G Vaughan Hudson B LOPP alternating with EVAP is superior to LOPP alone in the intial treatment of advanced Hodgkin's disease: Results of a British National Lymphoma Investigation trial J Clin Oncol 10 1992 1252 1258
49. Gobbi PG Pieresca C Federico M MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: A report from the Italian Lymphoma Study Group J Clin Oncol 11 1993 712 719
50. Salvagno L Soraru M Sotti G Hybrid MOPP/ABVD and radiotherapy in advanced Hodgkin's disease Ann Oncol 6 1995 173 179
51. Rosenberg SA Kaplan HS The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962–1984 Int J Radiat Oncol Biol Phys 11 1985 5 22
52. Grozea PN Depersio EJ Coltman CA Chemotherapy alone vs combined modality therapy for stage III disease: A 5-year follow-up of a SWOG study Cavalli F Bonadonna G Rozencweig M Malignant Lymphomas and Hodgkin's disease: Experimental and Therapeutic Advances. Proceedings of the Second International Conference on Malignant Lymphomas 1985 Martinus Nijhoff Boston, MA
53. Crowther D Wagstaff J Deakin D A randomized study comparing chemotherapy alone with chemotherapy followed by radiotherapy in patients with pathologically staged IIIA Hodgkin's disease J Clin Oncol 2 1984 892 897
54. Pavlovsky S Santarelli MT Sackmann Muriel F Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage III–IV A & B Hodgkin's disease Ann Oncol 3 1992 533 537
55. Yelle L Bergsagel D Basco V Combined modality therapy of Hodgkin's disease: 10-year results of National Cancer Institute of Canada Clinical Trials Group multicenter clinical trial J Clin Oncol 9 1991 1983 1993
56. (abstr) Fabian C Dahlberg S Miller T Efficacy of low dose involved field (LDIF) XRT in producing and maintaining CR following PR induction with MOP-BAP chemotherapy in Hodgkin's disease: Results of Southwest Oncology Group Study 7808 Proceedings of the American Society of Clinical Oncology 8 1989 253
57. (editorial) Hoppe RT The Prosnitz/Roberts article reviewed Oncology 6 1992 132 137
58. Horning SJ Adhikari A Rizk N Effect of treatment for Hodgkin's disease on pulmonary function: Results of a prospective study J Clin Oncol 12 1994 297 305
59. (abstr) Hirsch A Vander Els N Gomez EG The effect of ABVD chemotherapy with and without mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease Int J Radiat Oncol Biol Phys 30 S1 1994 168
60. Santoro A Bonadonna G Valagussa P Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy J Clin Oncol 5 1987 27 37
61. Brice P Tredaniel J Monsuez JJ Cardiopulmonary toxicity after three courses of ABVD and mediastinal irradiation in favorable Hodgkin's disease Ann Oncol 2 suppl 2 1991 73 76
62. Allavena C Conroy T Aletti P Late cardiopulmonary toxicity after treatment for Hodgkin's disease Br J Cancer 65 1992 908 912
63. Kaldor JM Day NE Clarke EA Leukemia following Hodgkin's disease N Engl J Med 322 1990 7 13
64. Valagussa P Santoro A Fossati-Bellani F Second acute leukemia and other malignancies following treatment for Hodgkin's disease J Clin Oncol 4 1986 830 837
65. Cimino G Papa G Tura S Second primary cancer following Hodgkin's disease: Updated results of an Italian multicentric study J Clin Oncol 9 1991 432 437
66. Tucker MA Coleman CN Cox RS Risk of second cancers after treatment for Hodgkin's disease N Engl J Med 318 1988 76 81
67. Coltman CA Jr Dixon DO Second malignancies complicating Hodgkin's disease: A Southwest Oncology Group 10-year followup Cancer Treatment Reports 66 1982 1023 1033
68. Lavey RS Eby NL Prosnitz LR Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas Cancer 66 1990 80 88
69. Hoppe RT Secondary leukemia and myelodysplastic syndrome after treatment for Hodgkin's disease Leukemia 6 suppl 4 1992 155 157
70. Salvagno L Simonato L Soraru M Secondary leukemia following treatment for Hodgkin's disease Tumori 79 1993 103 107
71. Boivin J-F Hutchison GB Zauber AG Incidence of second cancers in patients treated for Hodgkin's disease J Natl Cancer Inst 87 1995 732 741
72. van Leeuwen FE Chorus AMJ van den Belt-Dusebout AW Leukemia risk following Hodgkin's disease: Relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage J Clin Oncol 12 1994 1063 1073
73. Biti G Cellai E Magrini SM Second tumors and leukemia after treatment for Hodgkin's disease: An analysis of 1121 patients from a single institution Int J Radiat Oncol Biol Phys 29 1994 25 31
74. Hess CF Kortmann RD Schmidberger H How relevant is secondary leukemia for initial treatment selection in Hodgkin's disease Eur J Cancer 30A 1994 1441 1447
75. Glicksman AS Pajak TF Gottlieb A Second malignant neoplasms in patients successfully treated for Hodgkin's disease: A Cancer and Leukemia Group B study Cancer Treatment Reports 66 1982 1035 1044
76. van Leeuwen FE Klokman WJ Hagenbeek A Second cancer risk following Hodgkin's disease: A 20-year follow-up study J Clin Oncol 12 1994 312 325
77. Abrahamsen JF Andersen A Hannisdal E Second malignancies after treatment of Hodgkin's disease: The influence of treatment, follow-up time, and age J Clin Oncol 11 1993 255 261
78. Tucker MA Solid second cancers following Hodgkin's disease Hematol Oncol Clin North Am 7 1993 389 400
79. Henry-Amar M Second cancer after the treatment for Hodgkin's disease: A report from the International Database on Hodgkin's disease Ann Oncol 3 suppl 4 1992 S117 S128
80. Kaldor JM Day NE Bell J Lung cancer following Hodgkin's disase: A case-control study Int J Cancer 52 1992 677 681
81. Hancock SL Tucker MA Hoppe RT Breast cancer after treatment of Hodgkin's disease J Natl Cancer Inst 85 1993 25 31
82. Doria R Holford T Farber LR Second solid malignancies after combined modality therapy for Hodgkin's disease J Clin Oncol 13 1995 2016 2022
83. Radford JA Cowan RA Flanagan M The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease J Clin Oncol 6 1988 940 946
84. Jochelson M Mauch P Balikian J The significance of the residual mediastinal mass in treated Hodgkin's disease J Clin Oncol 3 1985 637 640
85. Edwards CL Hayes RL Tumor scanning with gallium-67 citrate J Nucl Med 10 1969 103 105
86. Cooper DL Caride VJ Zloty M Gallium scans in patients with mediastinal Hodgkin's disease treated with chemotherapy J Clin Oncol 11 1993 1092 1098
87. King SC Reiman RJ Prosnitz LR Prognostic importance of restaging gallium scans following induction chemotherapy for advanced Hodgkin's disease J Clin Oncol 12 1994 306 311
88. Even-Sapir E Bar-Shalom R Israel O Single-photon emission computed tomography quantitation of gallium citrate uptake for the differentiation of lymphoma from benign hilar uptake J Clin Oncol 13 1995 942 946
89. Herskovic A Martz K Al-Sarraf M Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus N Engl J Med 326 1992 1593 1598
90. Krook JE Moertel CG Gunderson LL Effective surgical adjuvant therapy for high-risk rectal carcinoma N Engl J Med 324 1991 709 715
91. Cummings BJ Keane TJ O'Sullivan B Epidermoid anal cancer: Treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C Int J Radiat Oncol Biol Phys 21 1991 1115 1125
92. Perry MC Eaton WL Propert KJ Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung N Engl J Med 316 1987 912 918
93. Hagemeister FB Fuller LM Velasquez WS Two cycles of MOPP and radiotherapy: Effective treatment for stage IIIA and IIIB Hodgkin's disease Ann Oncol 2 1991 25 31
94. Vijayakumar S Myrianthopoulos LC An updated dose response analysis in Hodgkin's disease Radiother Oncol 24 1992 1 13
95. Hanks GE Kinzie JJ White RL Patterns of care outcome studies: Results of the national practice in Hodgkin's disease Cancer 51 1983 569 573
96. Gospodarowicz MK Sutcliffe SB Clark RM An analysis of supradiaphragmatic clinical stage I and II Hodgkin's disease treated with radiation alone Int J Radiat Oncol Biol Phys 22 1992 859 865
97. Brincker H Bentzen SM A reanalysis of available doseresponse and time-dose data in Hodgkin's disease Radiother Oncol 30 1994 227 230
98. Donaldson SS Link MP Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease J Clin Oncol 5 1987 742 749
99. Hunger SP Link MP Donaldson SS ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: The Stanford experience J Clin Oncol 12 1994 2160 2166
100. Maity A Goldwein JW Lange B Comparison of high-dose and low-dose radiation with and without chemotherapy for children with Hodgkin's disease J Clin Oncol 10 1992 929 936
101. Hudson MM Greenwald C Thompson E Efficacy and toxicity of multi-agent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease J Clin Oncol 11 1993 100 108
102. Oberlin O Leverger G Pacquement H Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: The experience of the French Society of Pediatric Oncology J Clin Oncol 10 1992 1602 1608
103. Dowling SW Peschel RE Portlock CS Mediastinal irradiation in combined modality therapy for Hodgkin's disease Int J Radiat Oncol Biol Phys 19 1990 543
104. Dowling SW Peschel RE Portlock CS Mediastinal irradiation in combined modality therapy for Hodgkin's disease Int J Radiat Oncol Biol Phys 19 1990 546